Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.


From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Read more about Garaizar and the TMC Venture Fund here.

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Read more about Klemp and Moleculin here.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Read more about Sutaria and ST&F here.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Read more about Jones and iCRYO here.


Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Houston biotech company aims to enhance oncology treatment of highly resistant cancers

Med tech

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Google teams up with Rice University to launch AI-focused accelerator

eyes on AI

Google Public Sector is teaming up with Rice University to drive early-stage artificial intelligence innovation and commercialization via the new Rice AI Venture Accelerator, or RAVA.

RAVA will use Google Cloud technology and work with venture capital firm Non Sibi Ventures to connect high-potential AI-focused startups with public and private sector organizations. The incubator will be led by Rice Nexus, which launched earlier this year in the Ion District as an AI-focused "innovation factory.”

“Google Public Sector is proud to partner with a leading institution like Rice University to launch the Rice AI Venture Accelerator,” Reymund Dumlao, director of state and local government and education at Google Public Sector, said in a news release. “By providing access to Google Cloud’s cutting-edge AI, secure cloud infrastructure and expertise, we’re enabling the next generation of AI pioneers to develop solutions that address critical challenges across industries and within the public sector. This unique partnership between education and industry will give participants access to cutting-edge research, leading technologists, specialized resources and a collaborative academic ecosystem, fostering an environment for rapid innovation and growth.”

Participants will have access to Google Public Sector’s AI leadership as well as experts from Rice’s Ken Kennedy Institute, which focuses on AI and computing research. It will be led by Sanjoy Paul, Rice Nexus’ inaugural executive director. Paul previously worked at Accenture LLC as a managing director of technology and is a lecturer in Rice's Department of Computer Science.

Rice Nexus will serve as the physical hub for RAVA, but the program will support AI startups from across the U.S., as part of Rice’s Momentous strategic plan, according to the university.

“This hub enables AI startups to go beyond building minimum viable products that meet industry privacy standards by utilizing the latest AI technologies from Google Cloud,” Paul said in the news release. “Our goal is to maximize the return on investment for our corporate partners, driving meaningful innovation that will have lasting impact on their industries.”

The 10,000-square-foot Rice Nexus space currently serves as home base for several startups with ties to Rice, including Solidec, BeOne Sports and others. Read more about the new incubation space here.

Houston’s love for live streaming is growing – and the internet needs to keep up

Tech-Heavy Households

One thing Houston isn’t slowing down on is its love for live streaming. Whether catching the big game, binge-watching a new series, or diving into the latest gaming releases, Houstonians are using the internet more than ever. And with nearly 4 million more people expected to move to the area by 2040, networks have to be ready.

More devices, more streaming, more demand
“Internet usage has been skyrocketing year after year," sts Foti Kallergis, Comcast Texas spokesperson. "The average Xfinity household now has 36 WiFi-connected devices, from smart TVs and phones to tablets, speakers, and even smart fridges."

More than 70 percent of all internet traffic is entertainment, with sports, streaming apps, and games leading the charge — especially here in Houston, where fans never miss a Texans game or a Rockets highlight.

In fact, the past year set records for Comcast’s Xfinity network, with the five biggest days of internet consumption ever happening just in the last few months of 2024, driven by huge sports events and gaming downloads.

A network built for what’s next
As more people move in and more devices come online, Xfinity is constantly upgrading its network to keep up — and stay ahead. Whether you’re working on your laptop, FaceTiming on your iPad, or scrolling on your phone, at home or on the go, the goal is simple: fast, reliable, and seamless connection.

Over the last decade, Comcast has poured $80 billion into strengthening its network and infrastructure across the country. That includes 300,000 miles of fiber — enough to circle the globe 12 times — supporting everything from everyday streaming to powering FEMA and the Department of Defense. And here in the greater Houston area, that same network supports thousands of small businesses, too.

Speed, security, and smarts built in
“It’s not just about staying connected — it’s about staying connected smarter,” adds Kallergis. “Comcast’s network is constantly working behind the scenes to make your experience better. In fact, Comcast rolled out over 350,000 upgrades last year alone, including faster speeds at no extra cost.”

Comcast Xfinity speed testPhoto courtesy of Comcast

And every 20 minutes, it tests over 4,000 data points across tens of millions of devices to keep things optimized.

Kallergis adds that if there's extra bandwidth, Xfinity modems automatically adjust. If there's a network issue, AI-powered tools fix 60 percent of cases before users even know something’s wrong. And if a fiber line is cut, Xfinity technicians are alerted instantly and know exactly where to go and what to do.

Powerful tools for your home
Great internet also depends on what’s inside your home. That’s why Comcast is rolling out the new XB10 modem — the fastest and most powerful yet. It can handle up to 300 devices at once (because let’s be real, we’re all tech-heavy households now).

And when it comes to security, Xfinity’s network has your back. Every device that connects is automatically shielded from sketchy sites; it's like having a mini cybersecurity team 24/7.

Looking ahead
At the end of the day, Houston’s internet needs are only going to grow. And Comcast is ready.

Whether you’re streaming the playoffs, jumping on a work call, or video chatting with family across the country, Xfinity is here to keep you connected to the moments that matter most.

8 Houston companies earn spots among Fortune's most innovative for 2025

top honor

Eight Houston companies have been named to Fortune’s third annual list of America’s Most Innovative Companies, joining another 16 from the state of Texas.

The group of 300 companies nationwide was rated based on production innovation, process innovation, and innovation culture, according to Fortune. In partnership with Statista, the magazine considered IP portfolios, employee, expert and customer opinions; and many other factors.

While many of the top-rated companies fell into the tech sector, Fortune reports that health care companies made up the largest portion of the 2025 list. Sixty-three honorees fell into the health care category, including Houston’s top-rated company, Houston Methodist.

Here’s which Houston companies made the list and where they ranked:

  • No. 35 — Houston Methodist
  • No. 54. — ExxonMobil
  • No. 137 — NRG Energy
  • No. 158 — Hewlett-Packard Enterprise
  • No. 169 — BMC Software
  • No. 175 — Texas Children’s Hospital
  • No. 227 — Sysco
  • No. 268 — Chevron

“This award is a true credit to the culture we have created around innovation and the incredible work of Roberta Schwartz, our Chief Innovation Officer, and her team at the Center for Innovation,” Marc Boom, CEO of Houston Methodist, said in a LinkedIn post. “They have really set the tone for how we can use innovation and technology to continue to deliver the highest quality care for our patients.”

Dallas-Fort Worth claimed the largest number of Texas companies on the list, with 11 headquartered in the metroplex. Houston was home to the second-most with eight hailing from the Bayou City. Austin is home to only four of the companies on the list, however, companies from the Capital City ranked higher on average, with Oracle, Tesla and Dell Technologies claiming the top three spots for the state. Beloved Texas grocer H-E-B was the one company to represent San Antonio.

Here's how the other Texas companies fared:

  • No. 6 — Oracle
  • No. 11 — Tesla
  • No. 14 — Dell Technologies
  • No. 37 — AT&T
  • No. 59 — Texas Instruments
  • No. 89 — Charles Schwab
  • No. 91 — McKesson
  • No. 113 — Jacobs Solutions
  • No. 125 — Baylor, Scott & White Health
  • No. 165 — Frontier Communications
  • No. 201— H-E-B
  • No. 210 — CBRE Group
  • No. 219 — TTEC Holdings
  • No. 223 — GameStop
  • No. 251 — American Airlines Group
  • No. 271 — Caterpillar

California-based tech conglomerate Alphabet Inc. topped the list for the third year in a row, and California companies again represented the majority of companies on the list, according to Fortune. Alphabet, Microsoft, Apple, IBM and Salesforce made up the top five, of which three are headquartered in California.

The 2025 group had a median revenue of $22 billion over the last 12 months, according to Fortune. See the full report here.